pharmaphorum

JANUARY 5, 2023

Despite the RSV vaccine threat, analysts at GlobalData have predicted that nirsevimab could reach $3 billion in annual revenue by 2030, assuming a launch in both Europe and the US this year. The post FDA starts review of Sanofi, AZ antibody for RSV prevention appeared first on.

FDA 52

FDA Healthcare Provider Marketing Healthcare 52

Pharmaceutical Technology

FEBRUARY 1, 2023

As paediatric hospital wings are flooded with an unprecedented number of respiratory syncytial virus (RSV) cases , healthcare workers have been overwhelmed by an unusually early peak of the RSV season. GlobalData is the parent company of Pharmaceutical Technology.

Pharma 64

Pharma Pharmaceutical FDA Healthcare Provider 64

Pharmaceutical Technology

JANUARY 27, 2023

Jakub Hlávka, PhD, the executive director of the Healthcare Markets Initiative and Fellow at the University of Southern California Schaeffer Center, suggests the strategy behind this new warranty program could “minimise the [financial and clinical] risk for the provider and for the patient”.

Patients 52

Patients Pharmaceutical Manufacturing Healthcare Provider 52

Pharmaceutical Technology

NOVEMBER 15, 2022

In May 2022, the CDC held a Health Alert Network (HAN) Health Advisory to update healthcare providers, public health departments, and the public on the potential for the recurrence of Covid-19 or “Covid-19 rebound.” These symptoms tend to remain mild and resolve themselves without the need for additional treatment.

Food and Drug Administration 64

Food and Drug Administration Government Distribution FDA 64

Pharmaceutical Technology

AUGUST 8, 2022

There’s no dearth of interest, however, in applying digital solutions to healthcare. The digital pill, now marketed by Otsuka Pharmaceuticals, is forecasted to make $27 million in sales in 2022, as per GlobalData. GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration 122

Food and Drug Administration FDA Medicine Patients 122

Pharmaceutical Technology

MAY 4, 2023

In April 2023, Washington State Senate passed the My Health, My Data Act designed to protect the “independence and dignity of individuals when making healthcare decisions.” To give healthcare providers the opportunity to focus on building patient trust, the Cassie CMP software provides full HIPAA and GDPR compliance.

Healthcare 52

Healthcare Healthcare Healthcare Provider Government 52

Pharmaceutical Technology

JUNE 8, 2023

If sponsors can harness it, this data can provide the key to saving time, labour and costs across the pharmaceutical value chain, ultimately bringing better drug products to patients sooner. When it is properly utilised, this information can be used to improve patient outcomes.

Management 52

Management Electronics Patients Pharmaceutical 52

Pharmaceutical Technology

NOVEMBER 30, 2022

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 98

Medical Manufacturing Insurance Side effects 98

Pharmaceutical Technology

JANUARY 6, 2023

As per the US Department of Justice release, Novartis Greece admitted making improper payments to Greek healthcare providers between 2009 and 2010, for an epidemiological study that was intended to increase sales of Novartis prescription drugs. By GlobalData. Evaluate the effects of COVID-19 on the sector. United Kingdom.

Pharmaceutical 97

Pharmaceutical Doctors Healthcare Provider Prescription 97

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData’s drugs database, only 5% of the globally marketed rare disease drugs are accessible in South and Central America. GlobalData is the parent company of Pharmaceutical Technology. For example, GlobalData predicts that in Q1 2023, Argentina’s total health spend will grow by 29.1%. billion deal.

Marketing 52

Marketing Pharmaceutical Pharma Pharmaceutical Sales 52

Pharmaceutical Technology

FEBRUARY 20, 2023

A 2022 report published by GlobalData found that in analysis of 12,698 clinical trials initiated over nine and a half years to June 2022 racial minority representation in pivotal studies is extremely low, accounting for 23.9% This may sound obvious, but it is still a major hurdle in drug development. of the clinical trial population globally.

Healthcare 52

Healthcare Healthcare Medicine Biopharma 52

Pharmaceutical Technology

MARCH 16, 2023

Dr Lisa Campo-Engelstein, a bioethicist, predicts that these factors and subsequent restrictions on statewide healthcare coverage will heavily restrict patient access to gender-affirming care. Campo-Engelstein is the director of the Institute for Bioethics & Health Humanities at the University of Texas Medical Branch, Galveston.

Ethics 144

Ethics Prescription Safety Healthcare 144

Pharmaceutical Technology

JUNE 9, 2023

Trial data is often vast and complex, and this can also make it difficult for healthcare providers to analyse the information in meaningful ways,” he explains. Throughout the process, patients should feel they can trust the healthcare company with their personal data. At all times, compliance stays top of mind.

Management 52

Management Healthcare Healthcare Patients 52

Pharmaceutical Technology

MAY 9, 2023

According to GlobalData analysis, the number of clinical trials with a decentralised and virtual component increased by 50% between 2020 and 2021, and this trend is here to stay. GlobalData analysis shows that Asia-Pacific is one of the fastest-growing geographies for clinical research, accounting for more than 50% of global trials in 2022.

Management 52

Management Patients Marketing Medical 52